β-adrenoceptor and 5-HT1A/1B receptor antagonist. pKB/pA2 values are 8.3 and 8.0 for 5-HT1A and 5-HT1B receptors respectively. Centrally active following systemic administration in vivo.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 348.44. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.87 mL||14.35 mL||28.7 mL|
|5 mM||0.57 mL||2.87 mL||5.74 mL|
|10 mM||0.29 mL||1.43 mL||2.87 mL|
|50 mM||0.06 mL||0.29 mL||0.57 mL|
References are publications that support the products' biological activity.
Chojnacka-Wojcik and Przegalinski (1991) Evidence for the involvement of 5-HT1A receptors in the anticonflict effect of ipsapirone in rats. Neuropharmacology 30 703 PMID: 1681448
Hoyer et al (1994) VII International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol.Rev. 46 157 PMID: 7938165
If you know of a relevant reference for SDZ 21009, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: SDZ 21009, supplier, β-adrenoceptor, beta-adrenoceptor, b-adrenoceptor, antagonists, 5-HT1A/1B, β-adrenergic, beta-adrenergic, b-adrenergic, Receptors, Non-Selective, Serotonin, SDZ21009, Non-selective, Adrenergic, Beta, Receptors, 5-HT1A, Receptors, 5-HT1B, Receptors, Non-selective, Adrenergic, Beta, Receptors, Tocris Bioscience
Citations for SDZ 21009
Citations are publications that use Tocris products.
Currently there are no citations for SDZ 21009. Do you know of a great paper that uses SDZ 21009 from Tocris? If so please let us know.
SDZ 21009 Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.